BRD9 and posterior cortical atrophy: Though BRD9 expression does not change with increases in Gleason grade and tumour stage, its expression was higher in metastatic PCa when compared to cancer-free patients and patients with local disease, suggesting that BRD9 could play a role as a prognostic biomarker and therapeutic target, especially in metastatic PCa.